Close Menu
Home » Alere Reports 2 Percent Dip in Q2 Revenues Despite Lift in Infectious Disease Sales

Alere Reports 2 Percent Dip in Q2 Revenues Despite Lift in Infectious Disease Sales

Sep 06, 2016
|
staff reporter

NEW YORK (GenomeWeb) – Alere today filed its financial results for the second quarter of 2016, reporting a 2 percent decrease in revenues year over year.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

That Rude Reviewer

ScienceInsider reports that rude and unprofessional paper reviewers are common and can have harmful effects.

New FDA Commish Confirmed

The US Senate has confirmed Stephen Hahn as the next commissioner of the Food and Drug Administration, according to the New York Times.

DNA Screening for Apple Employees

CNBC reports Apple is partnering with Color Genomics to offer its employees free DNA screening for disease.

Science Studies Describe Role for Microbiome-Derived Immunity, Platform to Develop Flavivirus Vaccines

In Science this week: researchers use CRISPR tool to find gut microbiome molecules involved in immunity, and more.

Dec
19
Featured Webinar

Evolution of Tumor Profiling in a Clinical Lab: Moving toward Comprehensive Genomic Profiling

Sponsored by
Qiagen

This webinar will provide a first-hand look at how a clinical lab evolved its tumor profiling workflow from a targeted panel approach toward comprehensive genomic profiling.  

Jan
28
Featured Webinar

Comprehensive Profiling of Myeloid Malignancies with Reliable Detection of FLT3 and CEBPA

Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

What's Popular?

In Molecular Diagnostics

  1. UK Study Details Liquid Biopsy's Ability to Guide Metastatic Breast Cancer Treatment

  2. ACMG Suggests Docs Evaluate All Breast Cancer Patients for Genetic Risk Test Suitability

  3. Tempus Acquires Commercial Lab, Precision Medicine Services Provider Akesogen

  4. NIH Awards $102.5M for Antibacterial Resistance Research, Dx Development

  5. Universal Genetic Testing in Breast Cancer May Result in More Harm Than Good, Experts Worry

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.